Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies

doi:10.1016/j.ecl.2013.05.009

Review

. 2013 Sep;42(3):489-501.

doi: 10.1016/j.ecl.2013.05.009.

Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies

Efrat Kravitz¹, James Schmeidler, Michal Schnaider Beeri

Affiliations

PMID: 24011882
PMCID: PMC3767929
DOI: 10.1016/j.ecl.2013.05.009

Review

Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies

Efrat Kravitz et al. Endocrinol Metab Clin North Am. 2013 Sep.

. 2013 Sep;42(3):489-501.

doi: 10.1016/j.ecl.2013.05.009.

Authors

Efrat Kravitz¹, James Schmeidler, Michal Schnaider Beeri

Affiliation

¹ The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.

PMID: 24011882
PMCID: PMC3767929
DOI: 10.1016/j.ecl.2013.05.009

Abstract

Type 2 diabetes, like dementia, disproportionately affects the elderly. Diabetes has consistently been associated with risk of dementia, mild cognitive impairment, and cognitive decline suggesting that cognitive compromise is a deleterious manifestation of diabetes. This review summarizes observational studies and clinical trials of diabetes medications and their respective associations and effects on cognitive outcomes. Despite biological plausibility, results from most human clinical trials have failed to show any efficacy in treating Alzheimer disease symptomatology and pathology. Clinical trials targeting vascular-related outcomes, diabetic patients, or cognitively normal elderly at risk for dementia, may provide greater cognitive benefits.

Keywords: Alzheimer disease; Cognitive decline; Dementia; Insulin; Insulin resistance; Oral hypoglycemics; Type 2 diabetes.

PubMed Disclaimer

Cited by

Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.
Cai R, Huang R, Han J, Sun H, Sun J, Xia W, Tian S, Dong X, Shen Y, Wang S. Cai R, et al. Sci Rep. 2017 Sep 26;7(1):12311. doi: 10.1038/s41598-017-12515-z. Sci Rep. 2017. PMID: 28951620 Free PMC article.
Prevalence and pattern of cognitive dysfunction in young adults and middle-aged patients with type-2 diabetes.
Chatterjee S, Bhattacharjee R, Sinha A, Maiti A, Mukherjee A, Ghosh R, Dubey S. Chatterjee S, et al. J Family Med Prim Care. 2025 Jun;14(6):2527-2537. doi: 10.4103/jfmpc.jfmpc_1900_24. Epub 2025 Jun 30. J Family Med Prim Care. 2025. PMID: 40726648 Free PMC article.
Berberine ameliorates rats model of combined Alzheimer's disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress.
Xuan WT, Wang H, Zhou P, Ye T, Gao HW, Ye S, Wang JH, Chen ML, Song H, Wang Y, Cai B. Xuan WT, et al. 3 Biotech. 2020 Aug;10(8):359. doi: 10.1007/s13205-020-02354-7. Epub 2020 Jul 29. 3 Biotech. 2020. PMID: 32832321 Free PMC article.
Pathophysiological Association Between Diabetes Mellitus and Alzheimer's Disease.
Agrawal M, Agrawal AK. Agrawal M, et al. Cureus. 2022 Sep 13;14(9):e29120. doi: 10.7759/cureus.29120. eCollection 2022 Sep. Cureus. 2022. PMID: 36258952 Free PMC article. Review.
Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients: A Real-World Cross-Sectional Study in Mysuru, India.
Kinattingal N, Mehdi S, Undela K, Wani SUD, Almuqbil M, Alshehri S, Shakeel F, Imam MT, Manjula SN. Kinattingal N, et al. J Pers Med. 2023 Mar 15;13(3):524. doi: 10.3390/jpm13030524. J Pers Med. 2023. PMID: 36983706 Free PMC article.

See all "Cited by" articles

References

1. Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706–1711. - PMC - PubMed
1. Alzheimer’s association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–245. - PubMed
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Press; 2000. Text Revision (DSM-IV-TR)
1. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661–666. - PubMed
1. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706–1711. - PMC - PubMed

[2] Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706–1711. - PMC - PubMed

[3] Alzheimer’s association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–245. - PubMed

[4] Alzheimer’s association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–245. - PubMed

[5] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Press; 2000. Text Revision (DSM-IV-TR)

[6] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Press; 2000. Text Revision (DSM-IV-TR)

[7] Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661–666. - PubMed

[8] Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661–666. - PubMed

[9] Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. - PubMed

[10] Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies

Affiliation

Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical